retatrutide phase 2 trial obesity triple agonist Lilly Prepares for FDA Filing Following Additional 3 Data in Diabetes, CVD Triple–Hormone-Receptor Agonist Retatrutide for Obesity
Pay in 4 interest-free payments of $5.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
























